Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease
Authors
Keywords
-
Journal
European Heart Journal-Cardiovascular Pharmacotherapy
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-06-10
DOI
10.1093/ehjcvp/pvab042
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
- (2020) Kamil F. Faridi et al.
- Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention
- (2020) Francesco Franchi et al. CIRCULATION
- Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus
- (2020) Davide Capodanno et al. CIRCULATION
- Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial
- (2019) Francesco Franchi et al. Journal of the American Heart Association
- Effects of the Peripheral Opioid Receptor Antagonist Methylnaltrexone on the PK and PD Profiles of Ticagrelor in Patients With Coronary Artery Disease Treated With Morphine
- (2019) Francesco Franchi et al. JACC-Cardiovascular Interventions
- Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
- (2019) Dirk Sibbing et al. JACC-Cardiovascular Interventions
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
- (2018) Francesco Franchi et al. CIRCULATION
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)
- (2018) Rachel C. Orme et al. CIRCULATION
- P2Y 12 -ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes
- (2018) Laurent Bonello et al. CIRCULATION
- ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
- (2018) Davide Capodanno et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease
- (2017) M. Zafar et al. THROMBOSIS AND HAEMOSTASIS
- Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus
- (2017) Fabiana Rollini et al. THROMBOSIS AND HAEMOSTASIS
- Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status
- (2017) Mark R. Thomas et al. THROMBOSIS AND HAEMOSTASIS
- Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
- (2017) Joseph M. Sweeny et al. Journal of the American Heart Association
- Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery DiseaseClinical Perspective
- (2016) Francesco Franchi et al. CIRCULATION
- A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study
- (2016) Fabiana Rollini et al. EUROPEAN HEART JOURNAL
- Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
- (2016) Robert F. Storey et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry
- (2015) U. Baber et al. Circulation-Cardiovascular Interventions
- Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention
- (2015) F. Franchi et al. Circulation-Cardiovascular Interventions
- Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2015) Francesco Franchi et al. JACC-Cardiovascular Interventions
- Glomerular Filtration Rate and Albuminuria for Detection and Staging of Acute and Chronic Kidney Disease in Adults
- (2015) Andrew S. Levey et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
- (2015) Marc P. Bonaca et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Chronic Kidney Disease on Platelet Reactivity and Outcomes of Patients Receiving Clopidogrel and Undergoing Percutaneous Coronary Intervention
- (2014) Fabio Mangiacapra et al. AMERICAN JOURNAL OF CARDIOLOGY
- KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD
- (2014) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease
- (2014) Dominick J. Angiolillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Novel antiplatelet agents in acute coronary syndrome
- (2014) Francesco Franchi et al. Nature Reviews Cardiology
- Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options
- (2013) Olivier Morel et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
- (2013) Usman Baber et al. THROMBOSIS AND HAEMOSTASIS
- Antithrombotic Therapy in Patients With Chronic Kidney Disease
- (2012) Davide Capodanno et al. CIRCULATION
- Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel
- (2012) L. BONELLO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus
- (2012) Antonio Tello-Montoliu et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
- (2011) José Luis Ferreiro et al. CIRCULATION
- Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment
- (2011) Kathleen Butler et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes
- (2010) Robert F. Storey et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy
- (2010) Dominick J. Angiolillo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More